Literature DB >> 21734803

Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA.

Chun-Nan Yeh1, Kun-Ju Lin, Tsung-Wen Chen, Ren-Ching Wu, Lee-Cheng Tsao, Ying-Tzu Chen, Wen-Hui Weng, Miin-Fu Chen.   

Abstract

AIM: To characterize a culture model of rat CCA cells, which were derived from a transplantable TTA-induced CCA and designated as Chang Gung CCA (CGCCA).
METHODS: The CGCCA cells were cultured at in vitro passage 12 times on a culture dish in DMEM medium. To measure the doubling time, 10(3) cells were plated in a 96-well plate containing the growth medium. The cells were harvested 4 to 10 d after seeding, and a standard MTT assay was used to measure the growth. The phenotype of CACCA cell and xenograft was determined by immunohistochemical study. We also determine the chromosomal alterations of CGCCA, G-banding and spectral karyotyping studies were performed. The CGCCA cell line was transplanted into the nude mice for examining its tumorigenicity. 2-Deoxy-2-((18)F)fluoro-D-glucose (FDG) autoradiography was also performed to evaluate the FDG uptake of the tumor xenograft.
RESULTS: The doubling time for the CGCCA cell line was 32 h. After transplantation into nude mice, FDG autoradiography showed that the tumors formed at the cell transplantation site had a latency period of 4-6 wk with high FDG uptake excluding necrosis tissue. Moreover, immunohistochemical staining revealed prominent cytoplasmic expression of c-erb-B2, CK19, c-Met, COX-II, EGFR, MUC4, and a negative expression of K-ras. All data confirmed the phenotypic features of the CGCCA cell line coincide with the xenograft mice tumors, indicating cells containing the tumorigenicity of CCA originated from CCA. In addition, karyotypic banding analysis showed that the diploid (2n) cell status combines with ring and giant rod marker chromosomes in these clones; either both types simultaneously appeared or only one type of marker chromosome in a pair appeared in a cell. The major materials contained in the marker chromosome were primarily identified from chromosome 4.
CONCLUSION: The current CGCCA cell line may be used as a non-K-ras effect CCA model and to obtain information and reveal novel pathways for CCA. Further applications regarding tumor markers or therapeutic targeting of CCA should be addressed accordingly.

Entities:  

Keywords:  Characterization; Cholangiocarcinoma; Establishment; Rat cell line; Thioacetamide

Mesh:

Year:  2011        PMID: 21734803      PMCID: PMC3129506          DOI: 10.3748/wjg.v17.i24.2924

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  High frequency of K-ras mutations in biliary duct carcinomas of cases with a long common channel in the papilla of Vater.

Authors:  E Hidaka; A Yanagisawa; M Seki; K Takano; T Setoguchi; Y Kato
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

2.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

3.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

Review 4.  Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies.

Authors:  A E Sirica; G H Lai; Z Zhang
Journal:  J Gastroenterol Hepatol       Date:  2001-04       Impact factor: 4.029

5.  Establishment of a novel rat cholangiocarcinoma cell culture model.

Authors:  G H Lai; A E Sirica
Journal:  Carcinogenesis       Date:  1999-12       Impact factor: 4.944

Review 6.  Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.

Authors:  Gautam Maulik; Amol Shrikhande; Takashi Kijima; Patrick C Ma; Paul T Morrison; Ravi Salgia
Journal:  Cytokine Growth Factor Rev       Date:  2002-02       Impact factor: 7.638

7.  FDG PET in the diagnosis of hilar cholangiocarcinoma.

Authors:  A Fritscher-Ravens; K H Bohuslavizki; D C Broering; L Jenicke; H Schäfer; R Buchert; X Rogiers; M Clausen
Journal:  Nucl Med Commun       Date:  2001-12       Impact factor: 1.690

8.  Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma.

Authors:  T Uenishi; K Hirohashi; S Kubo; T Yamamoto; H Hamba; H Tanaka; H Kinoshita
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

9.  Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes.

Authors:  S M Weber; W R Jarnagin; D Klimstra; R P DeMatteo; Y Fong; L H Blumgart
Journal:  J Am Coll Surg       Date:  2001-10       Impact factor: 6.113

10.  Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.

Authors:  Ling Xu; Martin Hausmann; Wolfgang Dietmaier; Silvia Kellermeier; Theresa Pesch; Manuela Stieber-Gunckel; Elisabeth Lippert; Frank Klebl; Gerhard Rogler
Journal:  BMC Cancer       Date:  2010-06-18       Impact factor: 4.430

View more
  4 in total

1.  Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.

Authors:  Ming-Huang Chen; Kun-Chun Chiang; Chi-Tung Cheng; Shih-Chiang Huang; Yeng-Yang Chen; Tsung-Wen Chen; Ta-Sen Yeh; Yi-Yin Jan; Hsi-Ming Wang; Jiang-Jie Weng; Peter Mu-Hsin Chang; Chun-Yu Liu; Chung-Pin Li; Yee Chao; Ming-Han Chen; Chi-Ying F Huang; Chun-Nan Yeh
Journal:  Oncotarget       Date:  2014-05-15

2.  Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma.

Authors:  Ming-Huang Chen; Chueh-Chuan Yen; Chi-Tung Cheng; Ren-Chin Wu; Shih-Chiang Huang; Chung-Shan Yu; Yi-Hsiu Chung; Chun-Yu Liu; Peter Mu-Hsin Chang; Yee Chao; Ming-Han Chen; Yu-Fen Chen; Kun-Chun Chiang; Ta-Sen Yeh; Tzu Chi Chen; Chi-Ying F Huang; Chun-Nan Yeh
Journal:  Oncotarget       Date:  2015-09-15

3.  Reappraisal of the therapeutic role of celecoxib in cholangiocarcinoma.

Authors:  Chun-Nan Yeh; Kun-Chun Chiang; Horng-Heng Juang; Jong-Hwei S Pang; Chung-Shan Yu; Kun-Ju Lin; Ta-Sen Yeh; Yi-Yin Jan
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

4.  Synthesis and evaluation of ortho-[18F] fluorocelecoxib for COX-2 cholangiocarcinoma imaging.

Authors:  Chi-Wei Chang; Chun-Nan Yeh; Yi-Hsiu Chung; Yong-Ren Chen; Shi-Wei Tien; Tsung-Wen Chen; Shiou-Shiow Farn; Ying-Cheng Huang; Chung-Shan Yu
Journal:  Drug Des Devel Ther       Date:  2018-05-24       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.